Optimal response to tislelizumab plus chemotherapy in metastatic triple-negative breast cancer: a case report and literature review

Overview of attention for article published in Frontiers in oncology, March 2024

Altmetric Badge

Mentioned by

twitter: 2 X users

Readers on

mendeley: 1 Mendeley

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 18,664 followers.

RT @FrontOncology: New research: Optimal response to tislelizumab plus chemotherapy in metastatic triple-negative breast cancer: a case rep…

29 Mar 2024

Reply Repost Favourite

New research: Optimal response to tislelizumab plus chemotherapy in metastatic triple-negative breast cancer: a case report and literature review: Metastatic triple-negative breast cancer (mTNBC) has the worst prognosis among breast cancer… https://t.co/ci

29 Mar 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.